Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

Novartis693 enrolled

Overview

This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

693

Conditions

Hypertension

Interventions

AliskirenDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Outpatients 18 years of age and older. 2. Patients with essential hypertension. Exclusion Criteria: Severe hypertension, Current diagnosis of heart failure, History or evidence of a secondary form of hypertension, Participation in any investigational drug study within one month of planned participation, Other protocol-defined inclusion/exclusion criteria may apply

Locations (2)

Unnamed facility

Investigative Centers, Germany

Novartis

Basel, Switzerland

Outcomes

Primary Outcomes

Change from baseline in diastolic blood pressure after 12 weeks

Secondary Outcomes

Change from baseline in systolic blood pressure after 12 weeks

Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 12 weeks

Blood pressure of < 140/90 mmHg after 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.